Related Experiment Video
Updated: Aug 9, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Clinical trial design in schizophrenia: implications for clinical decisions
1Department of Psychiatry and Psychotherapy, The Saarland University Hospitals, Homburg, Germany. frank.pajonk@uniklinik-saarland.de
Purpose Of Review:
Results from clinical trials do not necessarily provide information for decisions in clinical practice. This review aims to present strengths and limitations of different methodological types of clinical trials and to offer an overview of how knowledge from clinical trails can be distilled for clinical practice. Selected key questions in the treatment of schizophrenia are presented, with a focus on the possibilities and restrictions of translating trial results into real-world practice.
Recent Findings:
Randomized controlled trials are the gold standard for proving efficacy of a diagnostic or therapeutic procedure. They have a high degree of internal validity and a clear-cut message when conducted to good-quality standards but suffer from a lack of generalizability (external validity). Effectiveness studies evaluate effects of treatments under conditions approximating usual care. They may include patient-centred outcomes or health economic evaluations. According to the type of trial, specific problems arise in the interpretation of results. Typical examples are given for the treatment of acute exacerbations of schizophrenia, for relapse prevention and for the treatment of cognitive impairment.
Summary:
Clinical decisions have to be made upon the best knowledge. Therefore, well conducted studies addressing all major issues from all relevant perspectives are needed. The assessment of a treatment regimen for clinical utility requires both efficacy and effectiveness studies. An understanding of the design, analysis and conventions of both study types is essential for the interpretation of results and their translation to the clinical decision-making process.
Insights
Clinical trial results need careful interpretation for real-world practice. Understanding both efficacy and effectiveness studies is crucial for informed clinical decisions in schizophrenia treatment.
Area of Science:
- Psychiatry
- Clinical Trials Methodology
- Evidence-Based Medicine
Background:
- Clinical trial results often lack direct applicability to real-world patient care.
- Translating research findings into practical clinical decisions presents significant challenges.
Purpose of the Study:
- To review the strengths and limitations of various clinical trial methodologies.
- To provide guidance on distilling knowledge from clinical trials for clinical practice.
- To examine the application and constraints of trial result translation in schizophrenia treatment.
Main Methods:
- Review of different methodological types of clinical trials.
- Analysis of strengths and limitations of each trial type.
- Case examples focusing on schizophrenia treatment.
Main Results:
- Randomized controlled trials offer high internal validity but limited generalizability.
- Effectiveness studies assess treatments in real-world settings, including patient-centered and economic outcomes.
- Interpreting results requires understanding trial design and potential biases.
Conclusions:
- Clinical decisions demand the best available knowledge from well-designed studies.
- Assessing treatment utility necessitates both efficacy and effectiveness data.
- Understanding trial design is essential for interpreting results and clinical application.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Psychological and Sociocultural Causes of Schizophrenia
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
